Johnson & Johnson (JNJ) is seen as having a superior return and risk profile compared to Pfizer (PFE), mainly due to its consistent dividend growth over 63 years, lower payout ratio, ongoing share buybacks, and stable inventory levels. While Pfizer offers a much higher dividend yield (6.79%) and lower valuation, it has frozen dividends, halted buybacks, and shows more inventory volatility. This contrast highlights JNJ's operational stability and reliability for investors seeking steady income and growth. The analysis was shared by Envision Research, led by an experienced investor with over 20 years in the field.
Dividend Aristocrats such as Johnson & Johnson, Coca-Cola, and McDonald's provide reliable and growing passive income through decades of consistent dividend increases. Investing $10,000 in each of these stocks can generate a combined annual passive i...
Vanguard High Dividend Yield ETF (VYM) provides retirees with a stable income stream by distributing about 2.9% yield across roughly 540 stocks, minimizing concentration risk. Its portfolio includes large-cap dividend payers like JPMorgan Chase and P...
Johnson & Johnson shares increased 2.58% recently, supported by strong oncology sales and a solid Q1 earnings beat with $24.06 billion revenue and $2.70 EPS. The company raised its full-year revenue and EPS guidance, driven by growth in drugs like DA...
A 66-year-old retiree in Pennsylvania aimed to generate $55,000 annually from a $1.1 million portfolio but lost $2,400 in tax savings because her IRA automatically reinvested dividends shortly after she sold shares at a loss. This triggered the IRS w...
Nanobiotix and Johnson & Johnson presented early Phase 2 trial data for JNJ-1900 (NBTXR3), a novel nanoradioenhancer, in stage 3 inoperable non-small cell lung cancer (NSCLC). The treatment, combined with chemoradiotherapy and durvalumab, showed an o...
